MRS6MatthewSmithMatthew Raymond Smith, M.D., Ph.D.42.36389900000000-71.0677780000000076590Smith, MatthewRaymond617/724-5257Professor of Medicinecatalyst:eCommonsLogineCommons Loginprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofvivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson11042579Smith MR, Kaufman D, Oh W, Guerin K, Seiden M, Makatsoris T, Manola J, Kantoff PWCancerVinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study. Cancer. 2000 Oct 15; 89(8):1824-8.Cancer2000-10-15T00:00:002000Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.11901538Oh WK, Manola J, George DJ, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman DS, Shapiro CL, Kantoff PW, Smith MRCancer investigationA phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer Invest. 2002; 20(2):186-91.Cancer Invest2002-01-01T00:00:002002A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients.12578398Smith MRDrugs & agingBisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging. 2003; 20(3):175-83.Drugs Aging2003-01-01T00:00:002003Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.12837431Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PWUrologyFinasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology. 2003 Jul; 62(1):99-104.Urology2003-07-01T00:00:002003Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.14983482Diamond TH, Higano CS, Smith MR, Guise TA, Singer FRCancerOsteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004 Mar 01; 100(5):892-9.Cancer2004-03-01T00:00:002004Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.16983113Keating NL, O'Malley AJ, Smith MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyDiabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006 Sep 20; 24(27):4448-56.J Clin Oncol2006-09-20T00:00:002006Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.18317064Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman REJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerZoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 2008 Mar; 3(3):228-36.J Thorac Oncol2008-03-01T00:00:002008Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.12231036Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart CUrologyOverview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6.Urology2002-09-01T00:00:002002Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.19671656Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl CThe New England journal of medicineDenosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20; 361(8):745-55.N Engl J Med2009-08-11T00:00:002009Denosumab in men receiving androgen-deprivation therapy for prostate cancer.20141676Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PCJournal of the National Comprehensive Cancer Network : JNCCNNCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):162-200.J Natl Compr Canc Netw2010-02-01T00:00:002010NCCN clinical practice guidelines in oncology: prostate cancer.19996060Keating NL, O'Malley AJ, Freedland SJ, Smith MRJournal of the National Cancer InstituteDiabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010 Jan 06; 102(1):39-46.J Natl Cancer Inst2009-12-07T00:00:002009Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.20008614Smith MR, Kantoff PWJournal of clinical oncology : official journal of the American Society of Clinical OncologyChanges in PSA kinetics after DNA vaccine therapy-not so fast! J Clin Oncol. 2010 Feb 01; 28(4):e58; author reply e59.J Clin Oncol2009-12-14T00:00:002009Changes in PSA kinetics after DNA vaccine therapy-not so fast!21612474Smith MR, Zietman AL, Finkelstein JS, Wu CLThe New England journal of medicineCase records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer. N Engl J Med. 2011 May 26; 364(21):2044-51.N Engl J Med2011-05-26T00:00:002011Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.22302227Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DGThe oncologistChanges in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012; 17(2):212-9.Oncologist2012-02-02T00:00:002012Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.23093251Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DACancer discoveryAndrogen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012 Nov; 2(11):995-1003.Cancer Discov2012-10-23T00:00:002012Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.17914073Lipton A, Cook RJ, Major P, Smith MR, Coleman REThe oncologistZoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007 Sep; 12(9):1035-43.Oncologist2007-09-01T00:00:002007Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.16782912Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PWJournal of clinical oncology : official journal of the American Society of Clinical OncologyCelecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006 Jun 20; 24(18):2723-8.J Clin Oncol2006-06-20T00:00:002006Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.16804927Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MRCancerRandomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006 Aug 01; 107(3):530-5.Cancer2006-08-01T00:00:002006Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.17200361Smith MRClinical cancer research : an official journal of the American Association for Cancer ResearchObesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res. 2007 Jan 01; 13(1):241-5.Clin Cancer Res2007-01-01T00:00:002007Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.19276834Temel JS, Greer JA, Goldberg S, Vogel PD, Sullivan M, Pirl WF, Lynch TJ, Christiani DC, Smith MRJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerA structured exercise program for patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009 May; 4(5):595-601.J Thorac Oncol2009-05-01T00:00:002009A structured exercise program for patients with advanced non-small cell lung cancer.15072892Smith MRUrologyChanges in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004 Apr; 63(4):742-5.Urology2004-04-01T00:00:002004Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.15102674Michaelson MD, Marujo RM, Smith MRClinical cancer research : an official journal of the American Association for Cancer ResearchContribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res. 2004 Apr 15; 10(8):2705-8.Clin Cancer Res2004-04-15T00:00:002004Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer.15292315Smith MR, Fallon MA, Lee H, Finkelstein JSThe Journal of clinical endocrinology and metabolismRaloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004 Aug; 89(8):3841-6.J Clin Endocrinol Metab2004-08-01T00:00:002004Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.15535444Smith MRThe Journal of urologyOsteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol. 2004 Nov; 172(5 Pt 2):S52-6; discussion S56-7.J Urol2004-11-01T00:00:002004Osteoporosis and obesity in men receiving hormone therapy for prostate cancer.Authorship 117373212404279Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PWCancerSelective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer. 2002 Nov 01; 95(9):1864-8.Cancer2002-11-01T00:00:002002Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.12667423Michaelson MD, Smith MRCurrent oncology reportsThe role of bisphosphonates in the management of metastatic prostate cancer. Curr Oncol Rep. 2003 May; 5(3):245-9.Curr Oncol Rep2003-05-01T00:00:002003The role of bisphosphonates in the management of metastatic prostate cancer.12703221Michaelson MD, Smith MRCancer chemotherapy and biological response modifiersGenitourinary malignancies. Cancer Chemother Biol Response Modif. 2002; 20:471-91.Cancer Chemother Biol Response Modif2002-01-01T00:00:002002Genitourinary malignancies.Authorship 1077851129949495Smith MR, Yu MK, Small EJThe New England journal of medicineApalutamide and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 06 28; 378(26):2542.N Engl J Med2018-06-28T00:00:002018Apalutamide and Metastasis-free Survival in Prostate Cancer.21860001Saylor PJ, Lee RJ, Smith MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyEmerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011 Sep 20; 29(27):3705-14.J Clin Oncol2011-08-22T00:00:002011Emerging therapies to prevent skeletal morbidity in men with prostate cancer.22984218Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MDJournal of nuclear medicine : official publication, Society of Nuclear MedicineMultitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med. 2012 Nov; 53(11):1670-5.J Nucl Med2012-09-14T00:00:002012Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.23210129Keating NL, O'Malley A, Freedland SJ, Smith MRJournal of the National Cancer InstituteDiabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2012 Oct 03; 104(19):1518-23.J Natl Cancer Inst2012-10-03T00:00:002012Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.17721994Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman MLInternational journal of cancerGenetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.Int J Cancer2007-12-15T00:00:002007Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.22336376Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NLEuropean urologyAndrogen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012 Jun; 61(6):1119-28.Eur Urol2012-02-01T00:00:002012Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.23169517Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain MJournal of clinical oncology : official journal of the American Society of Clinical OncologyCabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9.J Clin Oncol2012-11-19T00:00:002012Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.18190632Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MRBJU internationalUse of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008 May; 101(9):1077-83.BJU Int2008-01-08T00:00:002008Use of androgen deprivation therapy for metastatic prostate cancer in older men.18348297Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JSCancerMetabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008 May 15; 112(10):2188-94.Cancer2008-05-15T00:00:002008Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.19660124Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman REBMC cancerNatural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 2009 Aug 06; 9:272.BMC Cancer2009-08-06T00:00:002009Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.20190794Efstathiou JA, Shipley WU, Zietman AL, Smith MRNature reviews. Clinical oncologyHormonal therapies: ADT for prostate cancer: true love or heartbreak? Nat Rev Clin Oncol. 2010 Mar; 7(3):130-2.Nat Rev Clin Oncol2010-03-01T00:00:002010Hormonal therapies: ADT for prostate cancer: true love or heartbreak?Authorship 114858622589396Saylor PJ, Karoly ED, Smith MRClinical cancer research : an official journal of the American Association for Cancer ResearchProspective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res. 2012 Jul 01; 18(13):3677-85.Clin Cancer Res2012-05-15T00:00:002012Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer.21898590Smith MR, Saad F, Egerdie B, Sieber P, Tammela TLj, Leder BZ, Ke C, Goessl CJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral ResearchDenosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. J Bone Miner Res. 2011 Dec; 26(12):2827-33.J Bone Miner Res2011-12-01T00:00:002011Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer.22013547Morgans AK, Smith MRJournal of osteoporosisRANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis. J Osteoporos. 2011; 2011:941310.J Osteoporos2011-10-15T00:00:002011RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis.18565878Smith MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyRapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past? J Clin Oncol. 2008 Jun 20; 26(18):2932-3.J Clin Oncol2008-06-20T00:00:002008Rapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past?18243498Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MREuropean urologyCardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol. 2008 Oct; 54(4):816-23.Eur Urol2008-01-15T00:00:002008Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.Authorship 1192220424012Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran SScience translational medicineIsolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010 Mar 31; 2(25):25ra23.Sci Transl Med2010-03-31T00:00:002010Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.21679977Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MRThe Journal of urologyFactors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2011 Aug; 186(2):482-6.J Urol2011-06-15T00:00:002011Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer.14610411Smith MRThe Journal of urologyBisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J Urol. 2003 Dec; 170(6 Pt 2):S55-7; discussion S57-8.J Urol2003-12-01T00:00:002003Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer.15046678Smith MRClinical prostate cancerChanges in body composition during hormonal therapy for prostate cancer. Clin Prostate Cancer. 2003 Jun; 2(1):18-21.Clin Prostate Cancer2003-06-01T00:00:002003Changes in body composition during hormonal therapy for prostate cancer.15226323Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JSJournal of clinical oncology : official journal of the American Society of Clinical OncologyBicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004 Jul 01; 22(13):2546-53.J Clin Oncol2004-07-01T00:00:002004Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.Authorship 124027118779620Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WUJournal of clinical oncology : official journal of the American Society of Clinical OncologyDiabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol. 2008 Sep 10; 26(26):4333-9.J Clin Oncol2008-09-10T00:00:002008Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.20404727Faris JE, Smith MRCurrent opinion in endocrinology, diabetes, and obesityMetabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes. 2010 Jun; 17(3):240-6.Curr Opin Endocrinol Diabetes Obes2010-06-01T00:00:002010Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.20643782Vallet S, Smith MR, Raje NClinical cancer research : an official journal of the American Association for Cancer ResearchNovel bone-targeted strategies in oncology. Clin Cancer Res. 2010 Aug 15; 16(16):4084-93.Clin Cancer Res2010-07-19T00:00:002010Novel bone-targeted strategies in oncology.15671557Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PWClinical cancer research : an official journal of the American Association for Cancer ResearchA phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005 Jan 01; 11(1):284-9.Clin Cancer Res2005-01-01T00:00:002005A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.15860850Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CSJournal of clinical oncology : official journal of the American Society of Clinical OncologyNatural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005 May 01; 23(13):2918-25.J Clin Oncol2005-05-01T00:00:002005Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.19555589Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CHJournal of the National Comprehensive Cancer Network : JNCCNNCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw. 2009 Jun; 7 Suppl 3:S1-32; quiz S33-5.J Natl Compr Canc Netw2009-06-01T00:00:002009NCCN Task Force Report: Bone Health in Cancer Care.20860650Coen JJ, Feldman AS, Smith MR, Zietman ALBJU internationalWatchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? BJU Int. 2011 May; 107(10):1582-6.BJU Int2010-09-22T00:00:002010Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?23228172Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DEThe New England journal of medicineAbiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48.N Engl J Med2012-12-10T00:00:002012Abiraterone in metastatic prostate cancer without previous chemotherapy.Authorship 1131545130738780Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano CThe Lancet. OncologyAddition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 03; 20(3):408-419.Lancet Oncol2019-02-06T00:00:002019Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.D001859Disorders84925210.40289Bone NeoplasmsD000726Chemicals & Drugs28913430.520138Androgen AntagonistsD007987Chemicals & Drugs26611870.615431Gonadotropin-Releasing HormoneAuthorship 124251Authorship 1223791Authorship 1246081D018931Chemicals & Drugs45214970.530951Antineoplastic Agents, HormonalD011471Disorders1451109990.194321Prostatic NeoplasmsEmeritusHealth Care PolicyMedicineRadiation OncologySurgeryHematology/OncologyOncologyBrigham and Women's HospitalDana-Farber Cancer InstituteHarvard Medical SchoolMassachusetts General HospitalDJK3DavidKuterDavid John Kuter, Dr.Phil., M.D.42.36389900000000-71.0677780000000036982Kuter, DavidProfessor of MedicinePLN1PaulNguyenPaul Linh Nguyen, M.D.42.33510370000000-71.106164900000003917Nguyen, PaulProfessor of Radiation OncologyJWC3JeffreyClarkJeffrey William Clark, M.D.42.36389900000000-71.0677780000000065616Clark, JeffreyAssociate Professor of MedicineJAE10JasonEfstathiouJason Alexander Efstathiou, M.D., Ph.D.42.36389900000000-71.0677780000000079577Efstathiou, JasonProfessor of Radiation OncologyAVD2AnthonyD'AmicoAnthony V. D'Amico, M.D., Ph.D.42.33510370000000-71.1061649000000046434D'Amico, AnthonyProfessor of Radiation OncologyPJS31PhilipSaylorPhilip J Saylor, M.D.42.36241700000000-71.0689370000000083359Saylor, PhilipAssistant Professor of MedicineNLK2NancyKeatingNancy Lynn Keating, M.D.42.33610940000000-71.1008845000000017235Keating, NancyProfessor of Health Care PolicyBD3BimalangshuDeyBimalangshu Dey, M.D.42.36389900000000-71.0677780000000014107Dey, BimalangshuAssociate Professor of MedicineBAC3BruceChabnerBruce A. Chabner, M.D.42.36389900000000-71.0677780000000040131Chabner, BruceProfessor of MedicineMDM1MarcMichaelsonMarc Dror Michaelson, M.D., Ph.D.42.36241700000000-71.0689370000000025243Michaelson, MarcAssociate Professor of MedicineRTP3RichardPensonRichard Thomas Penson, M.B.,B.S.42.36389900000000-71.0677780000000040002Penson, RichardAssociate Professor of MedicineMT54Mary-EllenTaplinMary-Ellen Taplin, M.D.42.33789600000000-71.1072493000000044971Taplin, Mary-EllenProfessor of MedicinePWK1PhilipKantoffPhilip Kantoff, M.D.42.33789600000000-71.1072493000000015015Kantoff, PhilipJerome and Nancy Kohlberg Professor of Medicine, Emeritus11204selected publications8.837720.00425492447research areas4.864370.014017764coauthor of541.97247.645260similar toAuthorship 1300706Authorship 1297907true1Professor of Radiation OncologyProfessor of Radiation Oncologytrue1Professor of MedicineProfessor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Associate Professor of SurgeryAssociate Professor of Surgerytrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Jerome and Nancy Kohlberg Professor of Medicine, EmeritusJerome and Nancy Kohlberg Professor of Medicine, Emeritustrue1Professor of Radiation OncologyProfessor of Radiation OncologyAuthorship 1324321Authorship 1239954Authorship 1391158Authorship 1391529Authorship 155688Authorship 1376889134273811Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi KEuropean journal of cancer (Oxford, England : 1990)Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. Eur J Cancer. 2021 09; 154:138-146.Eur J Cancer2021-07-14T00:00:002021Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.Authorship 1763011Authorship 219709123453420Keating NL, Liu PH, O'Malley AJ, Freedland SJ, Smith MREuropean urologyAndrogen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol. 2014 Apr; 65(4):816-24.Eur Urol2013-02-22T00:00:002013Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer.Authorship 2035151Authorship 1430404135131040Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi KThe Lancet. OncologyNiraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022 03; 23(3):362-373.Lancet Oncol2022-02-04T00:00:002022Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.Authorship 385154Authorship 4215072Authorship 2016425Authorship 2634181Authorship 2669961Authorship 3363501Authorship 36665522QT12Quoc-DienTrinhQuoc-Dien Trinh, M.D.119931Trinh, Quoc-DienAssociate Professor of SurgeryAuthorship 3949307true1Professor of Radiation OncologyProfessor of Radiation Oncologytrue1Professor of MedicineProfessor of Medicinetrue1Professor of Health Care PolicyProfessor of Health Care PolicyAuthorship 5675473Authorship 5519995Authorship 4574564Authorship 6406192Authorship 6377691Authorship 6380621Authorship 6400323Authorship 66213212Authorship 64247413Authorship 6434001Authorship 6357171Authorship 6570062Authorship 6601296Authorship 6607312Authorship 6456702Authorship 6523593Authorship 6526093Authorship 6579185Authorship 6535591Authorship 6559666Authorship 6415651Authorship 6616632Authorship 6394461Authorship 6630172Authorship 6654442Authorship 6656413Authorship 6488734Authorship 6416724Authorship 6436369Authorship 64567714Authorship 6474241Authorship 6529111Authorship 6408903Authorship 6602521Authorship 6456672Authorship 6558831Authorship 6486744Authorship 6522377Authorship 6650474Authorship 3562434Authorship 6571083Authorship 6364691Authorship 6557771Authorship 6670762Authorship 6570601Authorship 6531404Authorship 6664174Authorship 6526252Authorship 6412491Authorship 6599753Authorship 6641371Authorship 6661386Authorship 6468903Authorship 6650353Authorship 657131519741583Lipton A, Brown GA, Mundy GR, Roodman GD, Smith MRClinical advances in hematology & oncology : H&ONew opportunities for the management of cancer-related bone complications. Clin Adv Hematol Oncol. 2009 May; 7(5 Suppl 11):1-30; quiz 31.Clin Adv Hematol Oncol2009-05-01T00:00:002009New opportunities for the management of cancer-related bone complications.20952020Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AAThe Journal of urologyCardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol. 2010 Dec; 184(6):2313-9.J Urol2010-10-16T00:00:002010Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.21665138Hatoum HT, Lin SJ, Smith MR, Guo A, Lipton AClinical breast cancerTreatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin Breast Cancer. 2011 Jun; 11(3):177-83.Clin Breast Cancer2011-05-03T00:00:002011Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis.21523719Smith MR, Cook R, Lee KA, Nelson JBCancerDisease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011 May 15; 117(10):2077-85.Cancer2010-11-16T00:00:002010Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.21542749Smith MRThe New England journal of medicineEffective treatment for early-stage prostate cancer--possible, necessary, or both? N Engl J Med. 2011 May 05; 364(18):1770-2.N Engl J Med2011-05-05T00:00:002011Effective treatment for early-stage prostate cancer--possible, necessary, or both?20478658Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJCancer treatment reviewsMetastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010 Dec; 36(8):615-20.Cancer Treat Rev2010-05-15T00:00:002010Metastasis and bone loss: advancing treatment and prevention.20860651Kim HS, Moreira DM, Smith MR, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJBJU internationalA natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2011 Mar; 107(6):924-8.BJU Int2010-09-22T00:00:002010A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.23084529Morgans AK, Smith MRThe Urologic clinics of North AmericaBone-targeted agents: preventing skeletal complications in prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):533-46.Urol Clin North Am2012-09-04T00:00:002012Bone-targeted agents: preventing skeletal complications in prostate cancer.20723926Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MSThe Journal of urologyToremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010 Oct; 184(4):1316-21.J Urol2010-08-17T00:00:002010Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.22537796Keating NL, O'Malley AJ, Freedland SJ, Smith MREuropean urologyDoes comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol. 2013 Jul; 64(1):159-66.Eur Urol2012-04-19T00:00:002012Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?11525297Smith MRHematology/oncology clinics of North AmericaComplementary and alternative therapies for advanced prostate cancer. Hematol Oncol Clin North Am. 2001 Jun; 15(3):559-71.Hematol Oncol Clin North Am2001-06-01T00:00:002001Complementary and alternative therapies for advanced prostate cancer.23337762Lee RJ, Smith MRCancer journal (Sudbury, Mass.)Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J. 2013 Jan-Feb; 19(1):90-8.Cancer J2013-01-01T00:00:002013Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.22093187Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl CLancet (London, England)Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 07; 379(9810):39-46.Lancet2011-11-15T00:00:002011Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.21083514Hatoum HT, Lin SJ, Guo A, Lipton A, Smith MRCurrent medical research and opinionZoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin. 2011 Jan; 27(1):55-62.Curr Med Res Opin2010-11-18T00:00:002010Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis.22523198Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee KA, Coleman RE, Smith MRThe oncologistPrognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist. 2012; 17(5):645-52.Oncologist2012-04-20T00:00:002012Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration.19878635Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman GD, Smith MRJournal of the National Comprehensive Cancer Network : JNCCNThe science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw. 2009 Oct; 7 Suppl 7:S1-29; quiz S30.J Natl Compr Canc Netw2009-10-01T00:00:002009The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.21163673Saad F, Eastham JA, Smith MRUrologic oncologyBiochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol Oncol. 2012 Jul-Aug; 30(4):369-78.Urol Oncol2010-12-16T00:00:002010Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.21944083Smith MR, Klotz L, van der Meulen E, Colli E, Tankó LBThe Journal of urologyGonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol. 2011 Nov; 186(5):1835-42.J Urol2011-09-25T00:00:002011Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.23234631Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MSThe Journal of urologyToremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S45-50.J Urol2013-01-01T00:00:002013Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.22014807Smith MR, Malkowicz SB, Brawer MK, Hancock ML, Morton RA, Steiner MSThe Journal of urologyToremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol. 2011 Dec; 186(6):2239-44.J Urol2011-10-19T00:00:002011Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.22933844Lipton A, Smith MR, Ellis GK, Goessl CClinical Medicine Insights. OncologyTreatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol. 2012; 6:287-303.Clin Med Insights Oncol2012-08-16T00:00:002012Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.Authorship 5196111Authorship 5652287Authorship 577184Authorship 6751044Authorship 677373123959367Smith MRNature reviews. EndocrinologyCancer: ADT and acute kidney injury-causal or casual relationship? Nat Rev Endocrinol. 2013 Oct; 9(10):568-70.Nat Rev Endocrinol2013-08-20T00:00:002013Cancer: ADT and acute kidney injury-causal or casual relationship?23744754Taksler GB, Cutler DM, Giovannucci E, Smith MR, Keating NLCancerUltraviolet index and racial differences in prostate cancer incidence and mortality. Cancer. 2013 Sep 01; 119(17):3195-203.Cancer2013-06-06T00:00:002013Ultraviolet index and racial differences in prostate cancer incidence and mortality.Authorship 1541696Authorship 2718121Authorship 681534124043751Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl CJournal of clinical oncology : official journal of the American Society of Clinical OncologyDenosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013 Oct 20; 31(30):3800-6.J Clin Oncol2013-09-16T00:00:002013Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.Authorship 6898901024075621Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland CThe Lancet. OncologyAbiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013 Nov; 14(12):1193-9.Lancet Oncol2013-09-25T00:00:002013Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.Authorship 3209872Authorship 696037124302098Smith MRJAMAAndrogen deprivation therapy and acute kidney injury. JAMA. 2013 Dec 04; 310(21):2313.JAMA2013-12-04T00:00:002013Androgen deprivation therapy and acute kidney injury.Authorship 2088284Authorship 2494331Authorship 2326592Authorship 40069512Authorship 25919615Authorship 4239699Authorship 7100321Authorship 7152972Authorship 7165515Authorship 7231872Authorship 725135123073052Smith MRClinical advances in hematology & oncology : H&OSkeletal-related events in prostate cancer. Clin Adv Hematol Oncol. 2012 Aug; 10(8):535-6.Clin Adv Hematol Oncol2012-08-01T00:00:002012Skeletal-related events in prostate cancer.24284057Lee RJ, Smith MRClinical cancer research : an official journal of the American Association for Cancer ResearchCabozantinib and prostate cancer: inhibiting seed and disrupting soil? Clin Cancer Res. 2014 Feb 01; 20(3):525-7.Clin Cancer Res2013-11-27T00:00:002013Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?23428068Saylor PJ, Smith MR, O'Malley AJ, Keating NLEuropean urologyAndrogen-deprivation therapy and risk for biliary disease in men with prostate cancer. Eur Urol. 2014 Mar; 65(3):642-9.Eur Urol2013-02-12T00:00:002013Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.24590644Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50.J Clin Oncol2014-03-03T00:00:002014Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).Authorship 7262299Authorship 7257991524739897Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MRThe Lancet. OncologyEnzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014 May; 15(6):592-600.Lancet Oncol2014-04-14T00:00:002014Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.24638009Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, Luta G, Keating NL, Smith MR, Van Den Eeden SKJournal of clinical oncology : official journal of the American Society of Clinical OncologyEffectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014 May 01; 32(13):1324-30.J Clin Oncol2014-03-17T00:00:002014Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.Authorship 2265721Authorship 3035181Authorship 3464961Authorship 3554651Authorship 26645117Authorship 2743872Authorship 3440703Authorship 303991Authorship 7576451224806399Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang SL, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR, Michaelson MDClinical genitourinary cancerPrognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):317-24.Clin Genitourin Cancer2014-03-15T00:00:002014Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.Authorship 762216624971661Padhi D, Higano CS, Shore ND, Sieber P, Rasmussen E, Smith MRThe Journal of clinical endocrinology and metabolismPharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2014 Oct; 99(10):E1967-75.J Clin Endocrinol Metab2014-06-27T00:00:002014Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer.Authorship 765348125225437Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HIJournal of clinical oncology : official journal of the American Society of Clinical OncologyCabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014 Oct 20; 32(30):3391-9.J Clin Oncol2014-09-15T00:00:002014Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.Authorship 484811Authorship 768957125225438Smith MR, Halabi S, Small EJJournal of clinical oncology : official journal of the American Society of Clinical OncologyReply to F. Valcamonico et al. J Clin Oncol. 2014 Nov 10; 32(32):3685.J Clin Oncol2014-09-15T00:00:002014Reply to F. Valcamonico et al.Authorship 771403525204404Stuyckens K, Saad F, Xu XS, Ryan CJ, Smith MR, Griffin TW, Yu MK, Vermeulen A, Nandy P, Poggesi IClinical pharmacokineticsPopulation pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014 Dec; 53(12):1149-60.Clin Pharmacokinet2014-12-01T00:00:002014Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.Authorship 7789121324298897Sonpavde G, Pond GR, Armstrong AJ, Galsky MD, Leopold L, Wood BA, Wang SL, Paolini J, Chen I, Chow-Maneval E, Mooney DJ, Lechuga M, Smith MR, Michaelson MDBJU internationalRadiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU Int. 2014 Dec; 114(6b):E25-E31.BJU Int2014-07-17T00:00:002014Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.Authorship 553211Authorship 670223Authorship 4698631Authorship 43492Authorship 4737461Authorship 56102325097095Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MREuropean urologyAdverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015 May; 67(5):825-36.Eur Urol2014-08-02T00:00:002014Adverse effects of androgen deprivation therapy and strategies to mitigate them.Authorship 5328081Authorship 51154817Authorship 679675Authorship 2275891Authorship 3036533Authorship 33518611Authorship 2530821Authorship 3095351Authorship 3194472Authorship 5098152Authorship 2594862Authorship 2914141Authorship 3562113Authorship 4192751Authorship 426974Authorship 4298866Authorship 4381321Authorship 3534314Authorship 28129716Authorship 4528651Authorship 5163911Authorship 3138751Authorship 3143991Authorship 3385461Authorship 5142911424647231Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad FEuropean urologyUpdated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25.Eur Urol2014-03-06T00:00:002014Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).25601341Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DEThe Lancet. OncologyAbiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60.Lancet Oncol2015-01-16T00:00:002015Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.25524243Tsai HT, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Smith MR, Potosky ALThe Journal of urologyRisk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015 Jun; 193(6):1956-62.J Urol2014-12-15T00:00:002014Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.24631409Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HIEuropean urologyEffects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2015 Feb; 67(2):310-8.Eur Urol2014-02-20T00:00:002014Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.Authorship 2784422Authorship 2686321Authorship 3781271Authorship 41511Authorship 4386211Authorship 1731171Authorship 5518141Authorship 581459Authorship 3585028Authorship 8201852Authorship 8194902Authorship 8196441Authorship 8201883Authorship 8203787Authorship 8212354Authorship 8204661025829400Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, Vermeulen A, Poggesi I, Nandy PClinical cancer research : an official journal of the American Association for Cancer ResearchCorrelation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Clin Cancer Res. 2015 Jul 15; 21(14):3170-7.Clin Cancer Res2015-03-31T00:00:002015Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients.25425475Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H, Braun A, Fizazi KAnnals of oncology : official journal of the European Society for Medical OncologyDenosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015 Feb; 26(2):368-74.Ann Oncol2014-11-25T00:00:002014Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.Authorship 830519526059076Preston MA, Feldman AS, Coen JJ, McDougal WS, Smith MR, Paly JJ, Carrasquillo R, Wu CL, Dahl DM, Barrisford GW, Blute ML, Zietman AIUrologic oncologyActive surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years. Urol Oncol. 2015 Sep; 33(9):383.e9-16.Urol Oncol2015-06-06T00:00:002015Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years.Authorship 5117352Authorship 8332125Authorship 8339601526383955Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu CL, Shioda T, Ramaswamy S, Ting DT, Toner M, Maheswaran S, Haber DAScience (New York, N.Y.)RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015 Sep 18; 349(6254):1351-6.Science2015-09-18T00:00:002015RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.25985882Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJEuropean urologyImpact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015 Oct; 68(4):570-7.Eur Urol2015-05-16T00:00:002015Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.Authorship 8397436Authorship 8406491625687533Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Baron B, Hirmand M, Smith MREuropean urologyLong-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. Eur Urol. 2015 Nov; 68(5):787-94.Eur Urol2015-02-14T00:00:002015Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.26153564Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad FEuropean urologyMetastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. Eur Urol. 2015 Nov; 68(5):850-8.Eur Urol2015-07-04T00:00:002015Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.Authorship 4119186Authorship 428207Authorship 842297126151676Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, Kheoh T, Griffin TW, Molina A, Ryan CJThe Journal of urologyEfficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. J Urol. 2015 Nov; 194(5):1277-84.J Urol2015-07-04T00:00:002015Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.26362090Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JAEuropean urologyCardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. Eur Urol. 2016 Feb; 69(2):204-10.Eur Urol2015-09-09T00:00:002015Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.Authorship 8600954Authorship 8675449Authorship 869951226787433Krzywanski DM, Moellering DR, Westbrook DG, Dunham-Snary KJ, Brown J, Bray AW, Feeley KP, Sammy MJ, Smith MR, Schurr TG, Vita JA, Ambalavanan N, Calhoun D, Dell'Italia L, Ballinger SWCirculation. Cardiovascular geneticsEndothelial Cell Bioenergetics and Mitochondrial DNA Damage Differ in Humans Having African or West Eurasian Maternal Ancestry. Circ Cardiovasc Genet. 2016 Feb; 9(1):26-36.Circ Cardiovasc Genet2016-01-19T00:00:002016Endothelial Cell Bioenergetics and Mitochondrial DNA Damage Differ in Humans Having African or West Eurasian Maternal Ancestry.26954419Voog JC, Smith MR, Efstathiou JAJAMARadiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA. 2016 Mar 08; 315(10):1054-5.JAMA2016-03-08T00:00:002016Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.Authorship 47862411Authorship 886601426508309Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard SEuropean urologyPrior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol. 2016 05; 69(5):924-32.Eur Urol2015-10-24T00:00:002015Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.Authorship 8386872Assistant Professor1Associate Professor0Full ProfessorAuthorship 5703912Authorship 637091Authorship 908990127400947Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi KJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. J Clin Oncol. 2016 09 01; 34(25):3005-13.J Clin Oncol2016-07-11T00:00:002016Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.2008-05-31SLAVIN, PETER L1978-02-01General Clinical Research CenterM01RR0010662017-07-31SMITH, MATTHEW RAYMOND2006-07-06Midcareer Investigator AwardK24CA1219902005-08-31SMITH, MATTHEW RAYMOND2003-09-01ADAM: Androgen Deprivation vs. Antiandrogen MonotherapyR21CA101353Principal InvestigatorCo-Principal InvestigatorPrincipal InvestigatorAuthorship 819817Authorship 3283341Authorship 926229927084777Fu AZ, Tsai HT, Haque R, Ulcickas Yood M, Van Den Eeden SK, Cassidy-Bushrow AE, Zhou Y, Keating NL, Smith MR, Aaronson DS, Potosky ALWorld journal of urologyUse of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer. World J Urol. 2016 Dec; 34(12):1611-1619.World J Urol2016-04-15T00:00:002016Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.Authorship 4334751Authorship 4532356Authorship 5108085Authorship 9409488Authorship 943263128007467Fu AZ, Tsai HT, Haque R, Yood MU, Cassidy-Bushrow AE, Van Den Eeden SK, Keating NL, Smith MR, Zhou Y, Aaronson DS, Potosky ALThe Journal of urologyMortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 06; 197(6):1448-1454.J Urol2016-12-19T00:00:002016Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.27160947Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DEEuropean urologyPhase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol. 2016 12; 70(6):963-970.Eur Urol2016-05-06T00:00:002016Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.Authorship 4318541Authorship 4427961Authorship 949359427324190Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, De Porre P, Vermeulen A, Poggesi I, Nandy PClinical pharmacokineticsModeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Pharmacokinet. 2017 01; 56(1):55-63.Clin Pharmacokinet2017-01-01T00:00:002017Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.Authorship 956304227402060de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TWEuropean urologySubsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 04; 71(4):656-664.Eur Urol2016-07-09T00:00:002016Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.14610403Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PWThe Journal of urologyThird international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5.J Urol2003-12-01T00:00:002003Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.15535434Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PWThe Journal of urologyFourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol. 2004 Nov; 172(5 Pt 2):S3-5.J Urol2004-11-01T00:00:002004Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment.55 Fruit StMassachusetts General Hospital Cancer CenterYawkey 703055 Fruit StBoston02114MAAuthorship 964659227140926Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown JE, Shore ND, Saad F, Spencer A, Zhu L, Warner DJClinical cancer research : an official journal of the American Association for Cancer ResearchChanges in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clin Cancer Res. 2016 Dec 01; 22(23):5713-5721.Clin Cancer Res2016-05-02T00:00:002016Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.16258089Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CLJournal of clinical oncology : official journal of the American Society of Clinical OncologyGonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005 Nov 01; 23(31):7897-903.J Clin Oncol2005-11-01T00:00:002005Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.17369566Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007 Mar 20; 25(9):1038-42.J Clin Oncol2007-03-20T00:00:002007Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.Authorship 971569128314611Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJEuropean urologyClinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 07; 72(1):10-13.Eur Urol2017-03-15T00:00:002017Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.17999404Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MRCancerObesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer. 2007 Dec 15; 110(12):2691-9.Cancer2007-12-15T00:00:002007Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.18765113Smith MRCurrent urology reportsAndrogen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep. 2008 May; 9(3):197-202.Curr Urol Rep2008-05-01T00:00:002008Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.20141678Saylor PJ, Smith MRJournal of the National Comprehensive Cancer Network : JNCCNAdverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):211-23.J Natl Compr Canc Netw2010-02-01T00:00:002010Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.11413511Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JSCancerLow bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001 Jun 15; 91(12):2238-45.Cancer2001-06-15T00:00:002001Low bone mineral density in hormone-naïve men with prostate carcinoma.14581438Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MOJournal of clinical oncology : official journal of the American Society of Clinical OncologyCombined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003 Dec 01; 21(23):4277-84.J Clin Oncol2003-10-27T00:00:002003Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.12476433Pirl WF, Siegel GI, Goode MJ, Smith MRPsycho-oncologyDepression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology. 2002 Nov-Dec; 11(6):518-23.Psychooncology2002-11-01T00:00:002002Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study.12099579Smith MR, Kantoff PWInvestigational new drugsPeroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Invest New Drugs. 2002 May; 20(2):195-200.Invest New Drugs2002-05-01T00:00:002002Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer.15274067Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MSCancerNatural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004 Aug 01; 101(3):541-9.Cancer2004-08-01T00:00:002004Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.11575286Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JSThe New England journal of medicinePamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001 Sep 27; 345(13):948-55.N Engl J Med2001-09-27T00:00:002001Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.22245322Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MRThe Journal of urologyRacial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2012 Mar; 187(3):889-93.J Urol2012-01-15T00:00:002012Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.17826496Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad FUrologyPredictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology. 2007 Aug; 70(2):315-9.Urology2007-08-01T00:00:002007Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.11836291Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PWThe Journal of clinical endocrinology and metabolismChanges in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002 Feb; 87(2):599-603.J Clin Endocrinol Metab2002-02-01T00:00:002002Changes in body composition during androgen deprivation therapy for prostate cancer.15289492Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJJournal of clinical oncology : official journal of the American Society of Clinical OncologyProspective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15; 22(18):3705-12.J Clin Oncol2004-08-02T00:00:002004Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.15885273Smith MR, Nelson JBUrologyFuture therapies in hormone-refractory prostate cancer. Urology. 2005 May; 65(5 Suppl):9-16; discussion 17.Urology2005-05-01T00:00:002005Future therapies in hormone-refractory prostate cancer.16278476Michaelson MD, Smith MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyBisphosphonates for treatment and prevention of bone metastases. J Clin Oncol. 2005 Nov 10; 23(32):8219-24.J Clin Oncol2005-11-10T00:00:002005Bisphosphonates for treatment and prevention of bone metastases.18001802Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, Barnette KG, Rodriguez D, Steiner MSThe Journal of urologyToremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008 Jan; 179(1):152-5.J Urol2007-11-14T00:00:002007Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.18502900Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MRCA: a cancer journal for cliniciansManagement of complications of prostate cancer treatment. CA Cancer J Clin. 2008 Jul-Aug; 58(4):196-213.CA Cancer J Clin2008-05-23T00:00:002008Management of complications of prostate cancer treatment.19806171Saylor PJ, Smith MRNature reviews. UrologyProstate cancer: How can we improve the health of men who receive ADT? Nat Rev Urol. 2009 Oct; 6(10):529-31.Nat Rev Urol2009-10-01T00:00:002009Prostate cancer: How can we improve the health of men who receive ADT?19836774Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, Leder BZ, Goessl CThe Journal of urologyEffects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009 Dec; 182(6):2670-5.J Urol2009-12-01T00:00:002009Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.20124400Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai NCA: a cancer journal for cliniciansAndrogen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010 May-Jun; 60(3):194-201.CA Cancer J Clin2010-02-02T00:00:002010Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.12093432Smith MR, Fuchs V, Anderson EJ, Fallon MA, Manola JNutrition (Burbank, Los Angeles County, Calif.)Measurement of body fat by dual-energy X-ray absorptiometry and bioimpedance analysis in men with prostate cancer. Nutrition. 2002 Jul-Aug; 18(7-8):574-7.Nutrition2002-07-01T00:00:002002Measurement of body fat by dual-energy X-ray absorptiometry and bioimpedance analysis in men with prostate cancer.16434464Smith MR, Lee H, Nathan DMThe Journal of clinical endocrinology and metabolismInsulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006 Apr; 91(4):1305-8.J Clin Endocrinol Metab2006-01-24T00:00:002006Insulin sensitivity during combined androgen blockade for prostate cancer.16680835Smith MRCancer treatment reviewsMarkers of bone metabolism in prostate cancer. Cancer Treat Rev. 2006; 32 Suppl 1:23-6.Cancer Treat Rev2006-01-01T00:00:002006Markers of bone metabolism in prostate cancer.17062702Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King LClinical cancer research : an official journal of the American Association for Cancer ResearchAdvances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6209s-6212s.Clin Cancer Res2006-10-15T00:00:002006Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.17062721Smith MRClinical cancer research : an official journal of the American Association for Cancer ResearchTreatment-related osteoporosis in men with prostate cancer. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6315s-6319s.Clin Cancer Res2006-10-15T00:00:002006Treatment-related osteoporosis in men with prostate cancer.17562244Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, Berenson JRClinical lymphoma & myelomaClinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma. 2007 Mar; 7(5):346-53.Clin Lymphoma Myeloma2007-03-01T00:00:002007Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.18927277Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KNClinical cancer research : an official journal of the American Association for Cancer ResearchAdvancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res. 2008 Oct 15; 14(20):6387-95.Clin Cancer Res2008-10-15T00:00:002008Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.12787715Smith MRCancer treatment reviewsManagement of treatment-related osteoporosis in men with prostate cancer. Cancer Treat Rev. 2003 Jun; 29(3):211-8.Cancer Treat Rev2003-06-01T00:00:002003Management of treatment-related osteoporosis in men with prostate cancer.15338763Michaelson MD, Smith MRCancer chemotherapy and biological response modifiersGenitourinary malignancies. Cancer Chemother Biol Response Modif. 2003; 21:547-64.Cancer Chemother Biol Response Modif2003-01-01T00:00:002003Genitourinary malignancies.12548577Smith MRCancerDiagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer. 2003 Feb 01; 97(3 Suppl):789-95.Cancer2003-02-01T00:00:002003Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.23201471Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta KEuropean urologyNew and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 2013 Feb; 63(2):309-20.Eur Urol2012-11-23T00:00:002012New and emerging therapies for bone metastases in genitourinary cancers.16229955Smith MRCancer treatment reviewsZoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev. 2005; 31 Suppl 3:19-25.Cancer Treat Rev2005-10-14T00:00:002005Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.15555135Michaelson MD, Smith MR, Talcott JAClinical evidenceProstate cancer (metastatic). Clin Evid. 2003 Dec; (10):1012-22.Clin Evid2003-12-01T00:00:002003Prostate cancer (metastatic).18593621Smith MRUrologic oncologyOsteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. Urol Oncol. 2008 Jul-Aug; 26(4):420-5.Urol Oncol2008-07-01T00:00:002008Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.16406890Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman JThe Journal of urologyRisk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006 Jan; 175(1):136-9; discussion 139.J Urol2006-01-01T00:00:002006Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.22894598D'Amico AV, Smith MRThe New England journal of medicineClinical decisions. Screening for prostate cancer. N Engl J Med. 2012 Aug 16; 367(7):e11.N Engl J Med2012-08-16T00:00:002012Clinical decisions. Screening for prostate cancer.23065626Morgans AK, Smith MR, O'Malley AJ, Keating NLCancerBone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer. 2013 Feb 15; 119(4):863-70.Cancer2012-10-12T00:00:002012Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.19838837Saylor PJ, Keating NL, Smith MRJournal of general internal medicineProstate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S389-94.J Gen Intern Med2009-11-01T00:00:002009Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.20124128Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai NCirculationAndrogen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010 Feb 16; 121(6):833-40.Circulation2010-02-01T00:00:002010Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.Authorship 10092401328867562Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baron B, Krivoshik A, Hirmand M, Smith MRThe Journal of urologyLong-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results. J Urol. 2018 02; 199(2):459-464.J Urol2017-09-01T00:00:002017Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.15464919Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Ye Z, Nicol SJ, Stadler WMUrologic oncologyA multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004 Sep-Oct; 22(5):393-7.Urol Oncol2004-09-01T00:00:002004A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.16116596Lee H, McGovern K, Finkelstein JS, Smith MRCancerChanges in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005 Oct 15; 104(8):1633-7.Cancer2005-10-15T00:00:002005Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma.18398147Smith MR, Malkowicz SB, Chu F, Forrest J, Sieber P, Barnette KG, Rodriquez D, Steiner MSJournal of clinical oncology : official journal of the American Society of Clinical OncologyToremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol. 2008 Apr 10; 26(11):1824-9.J Clin Oncol2008-04-10T00:00:002008Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.19047297Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyCardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009 Jan 01; 27(1):92-9.J Clin Oncol2008-12-01T00:00:002008Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.15202584Smith MROncology (Williston Park, N.Y.)The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. Oncology (Williston Park). 2004 May; 18(5 Suppl 3):21-5.Oncology (Williston Park)2004-05-01T00:00:002004The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.12603918Michaelson MD, Talcott JA, Smith MRClinical evidenceProstate cancer: metastatic. Clin Evid. 2002 Dec; (8):881-90.Clin Evid2002-12-01T00:00:002002Prostate cancer: metastatic.12771706Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner NThe Journal of urologyRandomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003 Jun; 169(6):2008-12.J Urol2003-06-01T00:00:002003Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.16503765Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KAExpert opinion on investigational drugsToremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs. 2006 Mar; 15(3):293-305.Expert Opin Investig Drugs2006-03-01T00:00:002006Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.18945543Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UEEuropean urologyAndrogen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2009 Jan; 55(1):62-75.Eur Urol2008-10-14T00:00:002008Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.19286225Saylor PJ, Smith MRThe Journal of urologyMetabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009 May; 181(5):1998-2006; discussion 2007-8.J Urol2009-03-14T00:00:002009Metabolic complications of androgen deprivation therapy for prostate cancer.23553848Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MRClinical cancer research : an official journal of the American Association for Cancer ResearchA dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 01; 19(11):3088-94.Clin Cancer Res2013-04-03T00:00:002013A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.16474548Smith MRNature clinical practice. UrologyTherapy Insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol. 2005 Dec; 2(12):608-15; quiz 628.Nat Clin Pract Urol2005-12-01T00:00:002005Therapy Insight: osteoporosis during hormone therapy for prostate cancer.18097410Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner MNatureIsolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007 Dec 20; 450(7173):1235-9.Nature2007-12-20T00:00:002007Isolation of rare circulating tumour cells in cancer patients by microchip technology.18454791Smith MR, O'Malley AJ, Keating NLBJU internationalGonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? BJU Int. 2008 Jun; 101(11):1335-6.BJU Int2008-06-01T00:00:002008Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?15341675Smith MRCurrent treatment options in oncologyOsteoclast-targeted therapy for prostate cancer. Curr Treat Options Oncol. 2004 Oct; 5(5):367-75.Curr Treat Options Oncol2004-10-01T00:00:002004Osteoclast-targeted therapy for prostate cancer.15468186Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PWCancerRosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Oct 01; 101(7):1569-74.Cancer2004-10-01T00:00:002004Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.21208853Lee RJ, Saylor PJ, Smith MRClinical genitourinary cancerContemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer. 2010 Dec 01; 8(1):29-36.Clin Genitourin Cancer2010-12-01T00:00:002010Contemporary therapeutic approaches targeting bone complications in prostate cancer.16740758Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MRClinical cancer research : an official journal of the American Association for Cancer ResearchMarkers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3361-7.Clin Cancer Res2006-06-01T00:00:002006Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.22649143Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, Leder BZ, Goessl CJournal of clinical oncology : official journal of the American Society of Clinical OncologySarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012 Sep 10; 30(26):3271-6.J Clin Oncol2012-05-29T00:00:002012Sarcopenia during androgen-deprivation therapy for prostate cancer.17940447Smith MRCurrent opinion in endocrinology, diabetes, and obesityAndrogen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes. 2007 Jun; 14(3):247-54.Curr Opin Endocrinol Diabetes Obes2007-06-01T00:00:002007Androgen deprivation therapy for prostate cancer: new concepts and concerns.18308111Smith MR, Lee H, Fallon MA, Nathan DMUrologyAdipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008 Feb; 71(2):318-22.Urology2008-02-01T00:00:002008Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.20159814Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HIJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 20; 28(9):1496-501.J Clin Oncol2010-02-16T00:00:002010Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.20346051Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman ALBJU internationalThe 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22.BJU Int2010-03-15T00:00:002010The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer.18579314Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major PCancer treatment reviewsBone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008 Nov; 34(7):629-39.Cancer Treat Rev2008-06-24T00:00:002008Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.18802147Smith MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyOsteoporosis in men with prostate cancer: now for the fracture data. J Clin Oncol. 2008 Sep 20; 26(27):4371-2.J Clin Oncol2008-09-20T00:00:002008Osteoporosis in men with prostate cancer: now for the fracture data.20159824Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010 Mar 20; 28(9):1481-8.J Clin Oncol2010-02-16T00:00:002010Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.20399451Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MRThe Journal of urologyApplication of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010 Jun; 183(6):2200-5.J Urol2010-06-01T00:00:002010Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.21632851Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJClinical cancer research : an official journal of the American Association for Cancer ResearchPhase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61.Clin Cancer Res2011-06-01T00:00:002011Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.21319864Saylor PJ, Keating NL, Freedland SJ, Smith MRDrugsGonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs. 2011 Feb 12; 71(3):255-61.Drugs2011-02-12T00:00:002011Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.17443645Pirl WF, Greer JA, Goode M, Smith MRPsycho-oncologyProspective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology. 2008 Feb; 17(2):148-53.Psychooncology2008-02-01T00:00:002008Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy.20621630Lee RJ, Saylor PJ, Smith MRBoneTreatment and prevention of bone complications from prostate cancer. Bone. 2011 Jan; 48(1):88-95.Bone2010-05-31T00:00:002010Treatment and prevention of bone complications from prostate cancer.12231056Smith MRUrologyOsteoporosis during androgen deprivation therapy for prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):79-85; discussion 86.Urology2002-09-01T00:00:002002Osteoporosis during androgen deprivation therapy for prostate cancer.14654520Smith MRClinical cancer research : an official journal of the American Association for Cancer ResearchAntitumor activity of bisphosphonates. Clin Cancer Res. 2003 Nov 15; 9(15):5433-4.Clin Cancer Res2003-11-15T00:00:002003Antitumor activity of bisphosphonates.Authorship 100900915483039Michaelson MD, Rosenthal DI, Smith MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyLong-term bisphosphonate treatment of bone metastases from renal cell carcinoma. J Clin Oncol. 2004 Oct 15; 22(20):4233-4.J Clin Oncol2004-10-15T00:00:002004Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma.23234628Saylor PJ, Smith MRThe Journal of urologyMetabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4.J Urol2013-01-01T00:00:002013Metabolic complications of androgen deprivation therapy for prostate cancer.12465755Smith MRCancer metastasis reviewsOsteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev. 2002; 21(2):159-66.Cancer Metastasis Rev2002-01-01T00:00:002002Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer.12559282Smith MR, Fallon MA, Goode MJUrologyCross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology. 2003 Jan; 61(1):127-31.Urology2003-01-01T00:00:002003Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.